Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1393-1402

  Enriquez, Gerald G ^a   Rizvi, Syed A A ^b   D'Souza, Martin J ^c   Do, Duc P ^a  

^a CHICAGO STATE UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c MERCER UNIVERSITY   (United States)

Author keywords

Delivery system; Epigenetic therapy; Histone deacetylase inhibitor; Iron oxide; Microspheres; Sulforaphane

Indexed keywords

BOVINE SERUM ALBUMIN; DRUG CARRIER; HISTONE; IRON OXIDE; IRON OXIDE MICROSPHERE; MICROSPHERE; SULFORAPHANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEACETYLATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MICROTECHNOLOGY; MOUSE; NONHUMAN; SPRAY DRYING; TREATMENT OUTCOME; TUMOR VOLUME;

DELIVERY SYSTEM; EPIGENETIC THERAPY; HISTONE DEACETYLASE INHIBITOR; IRON OXIDE; MICROSPHERES; SULFORAPHANE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; ISOTHIOCYANATES; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED C57BL; MICROSPHERES; NEOPLASMS, EXPERIMENTAL; SERUM ALBUMIN, BOVINE;

BOVINAE; MUS;

EID: 84876274670     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S43479     Document Type: Article

References (50)

1. Bird A. Perceptions of epigenetics. Nature. 2007;447(7143):396-398.
2. Momparler RL. Cancer epigenetics. Oncogene. 2003; 22(42): 6479-6483.
3. Gronbaek K, Hother C, Jones PA. Epigenetic changes in cancer. APMIS. 2007;115(10):1039-1059.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
5. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769-784.
6. Butler JS, Koutelou E, Schibler AC, Dent SY. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics. 2012;4(2):163-177.
7. Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2012;2(5):405-413.
8. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457-463.
9. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103(5):1635-1640.
10. Chen X, Wang X, Wang Y, et al. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release. 145(1):17-25.
11. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005; 65(24):11631-11638.
12. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58(2):97-110.
13. Chen B, Wu W, Wang X. Magnetic iron oxide nanoparticles for tumor-targeted therapy. Curr Cancer Drug Targets. 2011;11(2): 184-189.
14. Colombo M, Carregal-Romero S, Casula MF, et al. Biological applications of magnetic nanoparticles. Chem Soc Rev. 2012;41(11): 4306-4334.
15. Jain S, Hirst DG, O'Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85(1010):101-113.
16. Mikhaylov G, Vasiljeva O. Promising approaches in using magnetic nanoparticles in oncology. Biol Chem. 2011;392(11):955-960.
17. Rosen JE, Chan L, Shieh DB, Gu FX. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine. 2012; 8(3):275-290.
18. Tietze R, Lyer S, Durr S, Alexiou C. Nanoparticles for cancer therapy using magnetic forces. Nanomedicine (Lond). 2012;7(3):447-457.
19. Hafeli UO, Sweeney SM, Beresford BA, Humm JL, Macklis RM. Effective targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results. Nucl Med Biol. 1995;22(2):147-155.
20. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008;5(2):316-327.
21. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005;2(3):194-205.
22. Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res. 2001;95(2):200-206.
23. Zhou S, Sun J, Sun L, et al. Preparation and characterization of interferon-loaded magnetic biodegradable microspheres. J Biomed Mater Res B Appl Biomater. 2008;87(1):189-196.
24. Hafeli UO, Sweeney SM, Beresford BA, Sim EH, Macklis RM. Magnetically directed poly(lactic acid) 90Y-microspheres: novel agents for targeted intracavitary radiotherapy. J Biomed Mater Res. 1994; 28(8):901-908.
25. Gazeau F, Levy M, Wilhelm C. Optimizing magnetic nanoparticle design for nanothermotherapy. Nanomeicine (Lond). 2008;3(6):831-844.
26. Hafeli UO. Magnetically modulated therapeutic systems. Int J Pharm. 2004;277(1-2):19-24.
27. Lokwani P, Goyal A, Gupta S, Songara RK, Singh N, Rathore KS. Pharmaceutical applications of magnetic particles in drug delivery system. Int J Pharm Res Dev. 2011;3(7):147-156.
28. Do DP, Pai SB, Rizvi SA, D'Souza MJ. Development of sulforaphane-encapsulated microspheres for cancer epigenetic therapy. Int J Pharm. 2010;386(1-2):114-121.
29. Little EG, Eide MJ. Update on the current state of melanoma incidence. Dermatol Clin. 2012;30(3):355-361.
30. Ho E, Clarke JD, Dashwood RH. Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr. 2009;139(12): 2393-2396.
31. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004;64(16):5767-5774.
32. Oettinger CW, D'Souza MJ, Akhavein N, Peer GT, Taylor FB, Kinasewitz GT. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB. J Microencapsul. 2007;24(4):337-348.
33. Sharma A, Harper CM, Hammer L, Nair RE, Mathiowitz E, Egilmez NK. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiopharm. 2004; 19(6):764-769.
34. Escribese MM, Sierra-Filardi E, Nieto C, et al. The prolyl hydroxylase PHD3 identifies proinflammatory macrophages and its expression is regulated by activin A. J Immunol. 2012;189(4):1946-1954.
35. Kalambur VS, Longmire EK, Bischof JC. Cellular level loading and heating of superparamagnetic iron oxide nanoparticles. Langmuir. 2007;23(24):12329-12336.
36. Bejugam NK, Uddin AN, Gayakwad SG, D'Souza MJ. Formulation and evaluation of albumin microspheres and its enteric coating using a spray-dryer. J Microencapsul. 2008;25(8):577-583.
37. Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CE, D'Souza MJ. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul. 2009;26(8):692-700.
38. Nettey H, Haswani D, D'Souza M, Oettinger C. In-vitro anti-microbial effect of encapsulated vancomycin on internalized Staph. aureus within endothelial cells. Drug Dev Ind Pharm. 2007;33(2):133-139.
39. Elsadek B, Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J Control Release. 2012;157(1):4-28.
40. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release. 2002;79(1-3):29-40.
41. Makino K, Nakajima T, Shikamura M, et al. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf B Biointerfaces. 2004;36(1):35-42.
42. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res. 2008;25(8): 1815-1821.
43. Alexiou C, Jurgons R, Schmid RJ, et al. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target. 2003;11(3):139-149.
44. Nacev A, Beni C, Bruno O, Shapiro B. Magnetic nanoparticle transport within flowing blood and into surrounding tissue. Nanomedicine (Lond). 2010;5(9):1459-1466.
45. Kassahun K, Davis M, Hu P, Martin B, Baillie T. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chem Res Toxicol. 1997;10(11):1228-1233.
46. Zhang Y, Munday R, Jobson HE, et al. Induction of GST and NQO1in cultured bladder cells and in the urinary bladders of rats by an extract of broccoli (Brassica oleracea italica) sprouts. J Agric Food Chem. 2006; 54(25):9370-9376.
47. Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 2006;20(3):506-508.
48. Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther. 2007;6(3):1013-1021.
49. Jia WJ, Liu JG, De Zhang Y, et al. Preparation, characterization, and optimization of pancreas-targeted 5-Fu loaded magnetic bovine serum albumin microspheres. J Drug Target. 2007;15(2):140-145.
50. Kang XJ, Dai YL, Ma PA, et al. Poly(acrylic acid)-modified Fe3O4microspheres for magnetic-targeted and pH-triggered anticancer drug delivery. Chemistry. 18(49):15676-15682.